PEP005 (ingenol mebutate) Gel
Sponsors
Peplin
Conditions
Actinic KeratosesActinic KeratosisPhoto-damageSeborrheic Keratosis
Phase 1
A Study to Evaluate the Photoirritation Potential of PEP005 (Ingenol Mebutate) Gel, 0.01% in Healthy Volunteers
CompletedNCT00850811
Start: 2009-02-28End: 2009-04-30Target: 30Updated: 2015-09-09
A Study to Evaluate the Photoallergic Potential of PEP005 (Ingenol Mebutate) Gel, 0.01% in Healthy Volunteers
CompletedNCT00850681
Start: 2009-02-28End: 2009-04-30Target: 50Updated: 2015-09-09
Phase 2
Study to Evaluate the Safety and Efficacy of PEP005 (Ingenol Mebutate) Gel, 0.015%, in Patients With Photo-damaged Skin
CompletedNCT01214577
Start: 2010-10-31End: 2011-01-31Updated: 2011-01-25
Study to Evaluate the Safety and Efficacy of PEP005(Ingenol Mebutate) Gel, 0.05%, in Patients With Seborrhoeic Keratosis
CompletedNCT01214564
Start: 2010-10-31End: 2010-12-31Updated: 2011-01-25
Phase 3
A Multicenter Study to Evaluate the Efficacy and Safety of PEP005 (Ingenol Mebutate) Gel When Used to Treat Actinic Keratoses (AKs) on the Non Head Locations
CompletedNCT00742391
Start: 2008-09-30End: 2009-02-28Updated: 2015-03-06
A Multicenter Study to Evaluate the Efficacy and Safety of PEP005 (Ingenol Mebutate) Gel When Used to Treat Actinic Keratoses (AKs) on the Non Head Locations
CompletedNCT00942604
Start: 2009-07-31End: 2009-10-31Updated: 2015-03-06